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Objectives: Pathological gambling (PG) is a highly prevalent and disabling impulse control
disorder. A range of psychopharmacological options are available for the treatment of PG,
includingselectiveserotoninreuptakeinhibitors,opioidreceptorantagonists,anti-addiction
drugs, and mood stabilizers. In our preliminary study, we examined the efﬁcacy of two
anti-addiction drugs, baclofen and acamprosate, in the treatment of PG. Materials and
Methods: Seventeen male gamblers were randomly divided into two groups. Each group
received one of the two drugs without being blind to treatment. All patients underwent a
comprehensivepsychiatricdiagnosticevaluationandcompletedaseriesofsemi-structured
interviews. During the 6-months of study, monthly evaluations were carried out to assess
improvement and relapses. Relapse was deﬁned as recurrent gambling behavior. Results:
None of the 17 patients reached the 6-months abstinence. One patient receiving baclofen
sustained abstinence for 4months. Fourteen patients succeeded in sustaining abstinence
for1–3months.Twopatientsstoppedattendingmonthlyevaluations.Conclusion:Baclofen
and acamprosate did not prove efﬁcient in treating pathological gamblers.
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INTRODUCTION
Pathologicalgambling(PG)isclassiﬁedintheDiagnosticandSta-
tisticalManualof MentalDisorders,FourthEdition,asanimpulse
control disorder (American Psychiatric Association, 2000). In the
InternationalClassiﬁcationof Diseasesof theWorldHealthOrga-
nization,PG is considered a habit and impulse disorder,alongside
kleptomania; trichotillomania, and pyromania, all of which are
characterized by an overwhelming urge to perform a harmful act
(World Health Organization, 1992). PG is a chronic, progressive,
male-dominant disorder, causing great personal and social con-
sequences such as suicide attempts, job loss, martial and family
problems, legal problems, and criminal behaviors (Dannon et al.,
2006; Iancu et al., 2008).
To date, a range of psychopharmacological options are avail-
able for the treatment of PG, including selective serotonin reup-
take inhibitors (SSRI),opioid receptor antagonists,anti-addiction
drugs, and mood stabilizers.
Multiplerandomized,double-blindaswellasopen-labelshort-
term (8, 12, or 16-week) trials have assessed pharmacotherapy
for the acute treatment of PG. As a group, these trials show an
overall mixed success with several double-blind studies failing to
show short-term efﬁcacy. To date, there have been four double-
blind trials of SSRIs for the treatment of PG. While two studies
showed short-term efﬁcacy (Hollander et al., 2000; Kim et al.,
2002), separate studies by Blanco et al. (2002) and Grant et al.
(2003)foundnosigniﬁcantstatisticalsuperiorityoftheSSRIagent
when compared to a placebo. Preliminary studies have examined
theuseof themoodstabilizers,topiramate(Dannonetal.,2005a),
and anti-addiction drug, bupropion (Black, 2004; Dannon et al.,
2005b,c), for the short-term treatment of PG with most studies
showing a beneﬁcial effect. In addition,the anti-addiction,opioid
antagonist naltrexone, has been shown to be beneﬁcial in treating
the cravings and urges associated with PG (Kim and Grant, 2001;
Kim et al., 2001).
It is well accepted in the clinical literature of PG that there are
several important limitations of existing short-term medication
trials: (1) variable rates of placebo response have been demon-
strated in the short-term studies, raising the question of whether
improvement seen in treatment groups may be related to non-
medication mechanisms of action; (2) PG typically has a chronic
course, and therefore acute remission of symptoms may not lead
toaclinicallysigniﬁcantimprovementinfunctioningif theremis-
sionisnotsustained;and(3)inallshort-termstudiespublishedto
date,remissionof gamblingsymptomswasjudged,atleastinpart,
accordingtopatients’self-reportsofgamblingbehaviorwhichmay
be biased (Dannon et al., 2007).
The opioid system controls the processing of reward, pleasure,
and pain, alongside gambling-related urges. Data suggests that
opioid receptor antagonists mediate their therapeutic action in
the treatment of addictive disorders through the modulation of
GABA neuronal input to dopamine neurons in the mesolimbic
pathway (Kim and Grant, 2001; Kim et al., 2001). GABA rep-
resents the main inhibitory neurotransmitter in the brain. High
levels of GABAB receptor expression in the limbic system indicate
a role in regulating emotional behavior (Addolorato et al., 2009).
The assumption is being that the GABA receptors may play a role
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in the pattern of urges, craving, and sense of enjoyment seen in
PG behavior (Addolorato et al., 2009).
The brain’s reward circuit, located in the nucleus accumbens,
ensures reinforcement of behaviors associated with species sur-
vivalandprocreation.Theopioidsystemisinvolvedintheprocess
of reward, pleasure, pain, and gambling-related urges. It has been
suggested that opioid receptor antagonists mediate their thera-
peutic action in the treatment of addictive disorders through the
modulation of GABA neuronal input to dopamine neurons in the
mesolimbic pathway (Addolorato et al., 2009). The above data
had led us to believe that GABA directed addiction drugs, such
as baclofen and acamprosate, might be efﬁcient in the treatment
of PG.
Alcohol has been proven to affect GABA neurotransmitters in
thebrain,andanti-addictiondrugshavebeenshowntobeefﬁcient
in decreasing the consumption and craving of alcohol. Acam-
prosate is believed to increase the effect on the inhibitory neu-
rotransmitter GABA and to decrease excitatory glutamate activity
at NMDA receptors (Addolorato et al., 2009). Baclofen is known
to suppress alcohol-stimulated dopamine release in the shell of
the nucleus accumbens of rats (Addolorato et al., 2009), and its
administration has been shown to promote alcohol abstinence
and reduce alcohol craving and intake; it has also been shown to
reduce anxiety (Addolorato et al., 2006).
Previous experience with anti-addiction medications, such as
bupropionandnaltrexone,hasbeenshowntobethemosteffective
for the treatment of PG (Kim and Grant, 2001; Kim et al., 2001;
Black, 2004; Dannon et al., 2005b,c). Based on the effectiveness
of anti-addiction drugs, we examined the efﬁcacy of two other
medications, baclofen and acamprosate. The difference between
the two groups is the system on which the drug affects; while
bupropionandnaltrexoneaffecttherewardsystemandtheneuro-
transmitter dopamine,the baclofen,and acamprosate could affect
the GABA system.
In our study, we tested the efﬁcacy of two addiction drugs,
acamprosate and baclofen, which stimulate the GABA receptors,
and have been proven to be effective in the treatment of alcohol
abuse (Addolorato et al., 2009).
1 Acamprosate
Acamprosate (calcium acetylhomotaurinate) is a simple deriv-
ative of the essential taurine amino acid which displays a
structural resemblance to gamma-amino butyric acid (GABA;
AmericanPsychiatricAssociation,2000).Itwasapprovedbythe
US FDA in 2004 for treatment of alcoholic patients to decrease
alcoholcravingafteralcoholdetoxiﬁcation.Acamprosateseems
to bind speciﬁcally to GABAB receptors (Boothby and Doer-
ing,2005).ItenhancesGABAreceptionandthetransmissionof
theGABAergicsystem,raisesthecontinuousalcoholabstinence
rate and doubles the days of cumulative abstinence from alco-
hol(BoothbyandDoering,2005).Acamprosateisnotasedative;
it does not possess addictive properties or provide reinforcing
effects.
2 Baclofen
Baclofen [beta-(4-chlorophenyl)-GABA] is a GABAB receptor
agonist that has been found to suppress both acquisition of
alcohol drinking behaviors in rats and daily alcohol intake in
alcohol experienced rats. It also suppresses alcohol-stimulated
dopamine released in the shell of the nucleus accumbens of rats
(Addolorato et al., 2009).
In alcohol dependant subjects, baclofen administration pro-
motes alcohol abstinence, induces the remission of withdrawal
symptoms, and reduces alcohol craving and alcohol intake
(Addolorato et al., 2006).
MATERIALS AND METHODS
STUDY SUBJECTS
Patients were referred to our clinic, from ambulatory services
throughout Israel,on account of our gambling disorder expertise.
All study patients signed an informed consent form after possible
side effects of the study medications were explained to them. Cur-
rent study was approved by local IRB committee to publish the
results of clinical trial. Patients also gave consent for family mem-
bers to be interviewed at the monthly follow-up visits. Inclusion
criteria included: PG diagnosis according to DSM-IV-TR crite-
ria and South Oaks gambling scale (SOGS) score of more than 5.
Exclusioncriteriaincluded:co-morbiditywithaxisonepsychiatric
disorders,neurologicaldisorders,alcoholandsubstanceabuse,and
treatment with any psychiatric medication in the month before to
the screening interview.
All patients underwent a comprehensive psychiatric diagnostic
evaluation and completed a series of semi-structured interviews
performed by a senior psychiatrist (PND).
Study subjects were evaluated on a monthly basis throughout
the duration of the study in order to assess measures of sustained
improvement (i.e., abstinence) and relapse. In this study, absti-
nence was strictly deﬁned as no gambling behavior (including any
formofgambling)duringthemonthprecedingthefollow-upvisit.
Relapse was deﬁned as any gambling behavior during the month
preceding the follow-up visit.
Instruments
We administered the Hamilton rating scale for anxiety (HARS;
Hamilton, 1959), the Hamilton depression rating scale (HDRS;
Hamilton, 1959, 1960), visual analog scale (VAS; Guy, 1976), and
theSouthOaksgamblingscreen(SOGS;LeisureandBlume,1987)
atbaseline.HARS,HDRS,VASwereadministeredateverymonthly
follow-up visit. The patients’ self-reports regarding amount of
time spent gambling was assessed at each follow-up visit although
a structured interview was not performed. Collateral information
regarding gambling behavior was collected from family members
at the monthly follow-up visits. All scales were administered by
the rater (TL) who was blind to drug treatment.
MEDICATION
Patients were randomly assigned to treatment with baclofen or
acamprosate. Treatment with baclofen was conducted as follows:
10mg per day for the ﬁrst 4days, than 20mg for the next 4days,
and than 30mg with stable condition up to 3weeks. Average
dosage of baclofen was 30mg per day (SD+7.5). Some patients
were treated with up to 50mg per day.
Treatment with acamprosate was conducted as follows:333mg
for the ﬁrst 4days than 666mg for a week and afterward 999mg
per day. Average dosage of acamprosate was 666mg (SD+174).
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Analysis
Statistical analysis was performed with t-test and ANOVA analy-
ses. Levels of signiﬁcance were set at 0.05,unless otherwise stated.
Also,twotailedt-testwaschosentoperformapartofthestatistical
analysis for independent samples.
RESULTS
Patients’ ages ranged between 19 and 69years (29.6±16.5).
Demographic data are summarized in Table 1.
The average SOGS score was 7.4+2.8 at baseline visit in two
groups. Also, HDRS, HARS, and VAS average scores were similar
and summarized in Table 2.
AccordingtotreatmentregimensT-testcomparisonhasshown
no statistical differences in HDRS, HARS, orVAS (Table 3).
Also, ANOVA analyses of VAS scores of patients treated with
either medication at baseline, after 1month and at relapse has
Table 1 | Demographic characteristics of the patients.
Baclofen
(N =9)
Acamprosate
(N =8)
P
values
Age 29.7±13.5 30.4±11.9 NS
Ethnicity %
North African decent 46 50% NS
Eastern European decent 30% 24% NS
Israeli born 24% 26% NS
Education %
12th grade 40% 40% NS
High School diploma 36% 40% NS
University 24% 20% NS
Employment %
Unemployed 18% 16% NS
Full/part time 82% 84% NS
Marital status %
Married 70% 66% NS
Widowed–divorced–separated 18% 20% NS
Never married 12% 14% NS
Table 2 | Statistical comparison of HDRS, HARS, andVAS scores of
patients treated with acamprosate and baclofen.
Visual
analog
scale
Hamilton
depression
rating
scale
Hamilton
anxiety
rating
scale
UnpairedT-TEST
at baseline
P >0.74 P >0.86 P >0.78
UnpairedT-TEST
after 1month of
treatment
completion
P >0.73 P >0.9 P >0.1
UnpairedT-TEST
at the time of
relapse
P >0.3 P >0.9 P >0.97
HDRS, Hamilton depression rating scale; HARS, Hamilton anxiety rating scale;
VAS, visual analog scale.
shown no statistical differences (P =0.9; f=0.3; lambda=1.5;
power=0.1).
ANOVA analyses of HDRS scores of patients treated with
either medication at baseline, after 1month and at relapse has
shown no statistical differences (P =0.92; f=0.26; lambda=1.3;
power=0.1).
ANOVA analyses of HARS scores of patients treated with
either medication at baseline, after 1month and at relapse has
shown no statistical differences (P =0.38; f=1.1; lambda=5.4;
power=0.3).
SIDE EFFECTS
Baclofen induced side effects were: weakness, apathy, headaches,
nausea. Acamprosate induced side effects included: nausea, vom-
iting head aches, muscle aches, stiffness. None of the patients
stopped the medication due these mild side effects.
DISCUSSION
None of the subjects from both groups succeeded to complete the
6-months of abstinence from gambling, we conclude that these
two medications were not effective to stop the gambling behavior.
However, recently published case report showed the effectiveness
of acamprosate. In this case patient was addicted to alcohol and
gambling (Raj,2010).
We postulate that the GABA system, in oppose to the reward
system,mostlikely,doesnothaveamajorroleinmanifestinggam-
bling in the PG. Dannon et al. (2006) and Iancu et al. (2008) have
reviewedPGliteratureandhavesuggestedacomprehensivetheory
of PG typology and treatment ramiﬁcations of each PG subtype.
Therefore,this model was further used in this study as it may well
beneﬁt treatment efﬁcacy for PG.
Dannonetal.(Dannonetal.,2006;Iancuetal.,2008)identiﬁed
atypologyconsistingofthreePGsubtypes:(1)addictivePG,which
is the largest subtype characterized by moderate severity of PG,
increase alcohol abuse and dependence and being predominantly
male. This subtype is suggested to best beneﬁt from opioid antag-
onists and anti-addiction drugs, (2) an obsessive compulsive PG
which is characterized by being predominantly female gamblers;
onset tends to be in midlife in response to a perceived psycho-
logical trauma, increased mood and anxiety co-morbidity. These
patients may best beneﬁt from anti-depressants such as SSRIs and
SNRIs and from psychotherapy addressing stress resolution and
coping mechanisms, and (3) an impulsive PG subtype character-
izedbyhighlevelsofrisk-takingbehaviors,littleabilitytoplanand
a tendency to spend large sums of money at one sitting. This sub-
typetendstopresentwithalcoholabuse,attentiondeﬁcitdisorder
(ADD) and other impulse control disorders. These patients may
respond best to lithium or other mood stabilizers/antiepileptic
drugs thought to target impulsive behavior.
The hypothetical model of sub typing is to explain the effec-
tivenessofdifferentmedicationsthroughdifferentsubtypesofPG.
In this preliminary study may have involved addicted subtype of
pathological gamblers but, may be the small sample size, could
not present equally all subtypes. However,the relatively low levels
of the patients ability to stop the gambling behavior more than a
month period demonstrates the ineffectiveness of these to drugs
in the treatment of gambling addiction.
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Table 3 | Average scores and SD of HDRS, HARS, andVAS.
Baclofen Acamprosate
Baseline After 1month At the time of relapse Baseline After 1month At the time of relapse
HDRS 10.1±2 10.6±1 10.6±1.5 10.3±1.5 10.7±1.7 10.7±1.2
HARS 11.25±1.66905 11.75±0.707 11.9±0.64 11±1.732 10.9±1.21 11.9±1.07
VAS 52.5±11.6 51.8±10.3 49.3±6.2 54.3±8.4 53.6±8.5 52.8±6.3
HDRS, Hamilton depression rating scale; HARS, Hamilton anxiety rating scale; VAS, visual analog scale.
The importance of pharmacological preliminary studies such
as our study ensues from the fact that no established pharma-
cotherapyexists.Potentiallyeffectivedirectionsforfuturepharma-
cotherapy need to be explored on the basis of preliminary studies,
or alternatively, as in this case, be renounced.
LIMITATIONS
The small sample size of this study limits the power of the study.
Anotherlimitationispatientswerenotblindtopharmacotherapy.
Athirdlimitationwasthelackofamedication-freeplacebocontrol
group. However, since the results of this study indicate the inefﬁ-
cacyof bothof themedications,thislimitationdoesnotlessenthe
strength of this particular study. We do recommend that further
studies using a placebo-controlled design should be carried out in
order to conﬁrm our preliminary ﬁndings.
ACKNOWLEDGMENTS
AuthorsthanktoMsTammyLevforherparticipationinthisstudy
REFERENCES
Addolorato, G., Leggio, L., Agabio,
R., Colombo, G., and Gasbar-
rini, G. (2006). Baclofen: a new
drug for the treatment of alcohol
dependence. Int. J. Clin. Pract. 60,
1003–1008.
Addolorato, G., Leggio, L., Cardone,
S., Ferrulli, A., and Gasbarrini, G.
(2009). Role of the GABA (B)
receptor system in alcoholism and
stress: focus on clinical studies and
treatment perspectives. Alcohol 43,
559–563.
American Psychiatric Association.
(2000). Diagnostic and Statistical
Manual of Mental Disorders, 4th
Edn. Washington, DC: American
Psychiatric Association.
Black, D. (2004). An open-label trial
of bupropion in the treatment of
pathological gambling. J. Clin. Psy-
chopharmacol. 24, 108–109.
Blanco, C., Petkova, E., Ibanez, A.,
and Sáiz-Ruiz, J. (2002). A pilot
placebo-controlled study of ﬂu-
voxamine for pathological gam-
bling. Ann. Clin. Psychiatry 14,
9–15.
Boothby, L. A., and Doering, P. L.
(2005). Acamprosate for the treat-
ment of alcohol dependence. Clin.
Ther. 27, 695–714.
Dannon, P. N., Lowengrub, K.,
Gonopolski, Y., Musin, E., and
Kotler, M. (2006). Pathological
gambling: a review of phenome-
nological models and treatment
modalities for an under recognized
psychiatric disorder. Prim Care
Companion J. Clin. Psychiatry 8,
334–339.
Dannon, P. N., Lowengrub, K., Musin,
E., Gonopolski, Y., and Kotler, M.
(2005a). Sustained release Bupro-
pion versus naltrexone in the
treatment of pathological gam-
bling. J. Clin. Psychopharmacol. 25,
593–596.
Dannon, P. N., Lowengrub, K.,
Gonopolski, Y., Musin, E., and
Kotler, M. (2005b). Topiramate
versus ﬂuvoxamine in the treatment
of pathological gambling: a ran-
domized, blind-rater comparison
study. Clin. Neuropharmacol. 28,
6–10.
Dannon, P. N., Lowengrub, K., Musin,
E., Gonoposki, Y., and Kotler, M.
(2005c). Sustained release bupro-
pion in the treatment of SSRI
noresponderpathologicalgamblers:
pilot study and review of the litera-
ture. Therapy 2, 753–759.
Dannon, P. N., Lowengrub, K., Musin,
E., Gonopolski, Y., and Kotler, M.
(2007). 12-month follow-up study
of drug treatment in pathological
gamblers: a primary outcome study.
J. Clin. Psychopharmacol. 27, 620–
624.
Grant, J. E., Kim, S. W., Potenza, M.
N., Blanco, C., Ibanez, A., Stevens,
L., Hektner, J. M., and Zaninelli.
R. (2003). Paroxetine treatment
of pathological gambling: a multi-
centre randomized controlled trial.
Int. Clin. Psychopharmacol. 18, 243–
249.
Guy, W. (1976). ECDEU Assessment
Manual for Psychopharmacology.
Rockville, MD: US Department of
Health,Education,andWelfarePub-
lication (ADM), 76–338.
Hamilton,M.(1959).Theassessmentof
anxiety states by rating. B r .J .M e d .
Psychol. 32, 50–55.
Hamilton, M. (1960). A rating scale
for depression. J. Neurol. Neurosurg.
Psychiatr. 23, 56–62.
Hollander, E., DeCaria, C. M., Finkell,
J. N., Begazab, T., Wongab, C. M.,
Cartwrightab, C. (2000). A ran-
domized double-blind ﬂuvoxam-
ine/placebo crossover trial in patho-
logic gambling. Biol. Psychiatry 47,
813–817.
Iancu, I., Lowengrub, K., Dembinsky,
Y., Kotler, M., and Dannon, P. N.
(2008). Pathological gambling: an
updateonneuropathphysiologyand
pharmacotherapy. CNS Drugs 22,
123–138.
Kim, S. W., Grant, J. E., Adson, D. E.,
Shin,Y. C., and Zaninelli, R. (2002).
A double-blind placebo-controlled
study of the efﬁcacy and safety
of paroxetine in the treatment of
pathological gambling. J. Clin. Psy-
chiatry 63, 501–507.
Kim, S. W., and Grant, J. E. (2001). An
open naltrexone treatment study in
pathological gambling disorder. Int.
Clin. Psychopharmacol. 16, 285–289.
Kim, S. W., Grant, J. E., Adson, D. E.,
andShin,Y.C.(2001).Double-blind
naltrexone and placebo comparison
study in the treatment of patholog-
ical gambling. Biol. Psychiatry 49,
914–921.
Leisure,H.,andBlume,S.B.(1987).The
South Oaks gambling screen (the
SOGS): a new instrument for the
identiﬁcation of pathological gam-
blers. Am. J. Psychiatry 144, 1184–
1188.
Raj, Y. P. (2010). Gambling on acam-
prosate:acasereport. J.Clin.Psychi-
atry 71, 1245–1246.
World Health Organization. (1992).
The ICD-10 Classiﬁcation of Men-
talandBehavioralDisorders:Clinical
Descriptions and Diagnostic Guide-
lines. Geneva:World Health Organi-
zation.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 31 March 2011; paper pend-
ing published: 01 May 2011; accepted:
23 May 2011; published online: 06 June
2011.
Citation: Dannon PN, Rosenberg O,
SchoenfeldNandKotlerM(2011)Acam-
prosate and baclofen were not effective
in the treatment of pathological gam-
bling: preliminary blind rater compar-
ison study. Front. Psychiatry 2:33. doi:
10.3389/fpsyt.2011.00033
This article was submitted to Frontiers
in Impulsivity, Compulsivity and Behav-
ioral Dyscontrol, a specialty of Frontiers
in Psychiatry.
Copyright © 2011 Dannon, Rosenberg,
Schoenfeld and Kotler. This is an open-
access article subject to a non-exclusive
license between the authors and Frontiers
Media SA, which permits use, distribu-
tion and reproduction in other forums,
provided the original authors and source
are credited and other Frontiers condi-
tions are complied with.
Frontiers in Psychiatry | Impulsivity, Compulsivity and Behavioral Dyscontrol June 2011 | Volume 2 | Article 33 | 4
.